Stockreport

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer [Yahoo! Finan...

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF Food and Drug Administration (FDA) has granted Fast Track designation to lunresertib in combination with camonsertib for the treatment of adult patients with CCNE1 ampli [Read more]